Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy

AIMS: Individuals with diabetes and chronic kidney disease (CKD) are at high risk for renal events. Recent trials of novel treatments have been negative, possibly because of variability in response to treatment of the target risk factor. Atrasentan is a selective endothelin A receptor antagonist tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Heerspink, Hiddo J. L., Andress, Dennis L., Bakris, George, Brennan, John J., Correa‐Rotter, Ricardo, Dey, Jyotirmoy, Hou, Fan Fan, Kitzman, Dalane W., Kohan, Donald, Makino, Hirofumi, McMurray, John, Perkovic, Vlado, Tobe, Sheldon, Wigderson, Melissa, Parving, Hans‐Henrik, de Zeeuw, Dick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Clinical Trial Design
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5969254/
https://www.ncbi.nlm.nih.gov/pubmed/29405626
http://dx.doi.org/10.1111/dom.13245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5969254/
https://www.ncbi.nlm.nih.gov/pubmed/29405626
http://dx.doi.org/10.1111/dom.13245

Ejemplares similares